Tasly Pharmaceutical's Net Profit Attributable to Parent Increases 15.63% in First Year After Integration into China Resources System

Tasly officially became a member of China Resources Sanjiu in 2025, and the market is highly focused on its integration process. The company’s annual report released on the evening of March 19 shows that the integration process exceeded market expectations in its first year, achieving operating revenue of 8.236 billion yuan in 2025; net profit attributable to shareholders was 1.105 billion yuan, a year-on-year increase of 15.63%. According to the company’s 15th Five-Year Plan, Tasly aims to double its industrial revenue and profits by the end of 2030, successfully ranking among China’s top pharmaceutical companies.

Steady and positive business performance

The annual report indicates that during the reporting period, the company’s operating performance remained stable, with revenue of 8.236 billion yuan, of which the main pharmaceutical industrial business revenue was 7.382 billion yuan, remaining relatively stable; net profit attributable to shareholders was 1.105 billion yuan, up 15.63% year-on-year.

Among the company’s three major business segments, cardiovascular and metabolic products generated 4.067 billion yuan; neurology and mental health products brought in 1.412 billion yuan; and digestive health products contributed 986 million yuan, with a growth of 3.91%.

Doubling profits by the end of 2030 in the 15th Five-Year Plan

Tasly’s annual report states that based on stable business, team stability, and core customer stability, guided by the principles of “value reshaping, business reshaping, organization reshaping, and spirit reshaping,” the company successfully completed the key tasks of the 100-day integration and first-year integration, achieving efficient resource integration with China Resources Sanjiu. The mutual empowerment effects continue to manifest, and the integration goals have been fully accomplished.

The annual report mentions that the company has established the corporate mission of “creating health for all” and the vision of “driven by innovation to become a leading enterprise in China’s pharmaceutical market.” It has systematically formulated the “15th Five-Year Plan” strategy: during this period, the company will adhere to innovation-driven development, focusing on three core therapeutic areas—cardiovascular and metabolic, neurology/psychiatry, and digestion—continuously expanding a pipeline of innovative products with high clinical value; by building a value cycle business model of “internal foundation building and external efficiency enhancement,” centered on clinical value, promoting coordinated development and sustained growth of internal and external businesses; through both endogenous growth and external expansion, the company aims to double its industrial revenue (to 15 billion yuan) and profits by the end of 2030, successfully ranking among China’s top pharmaceutical companies.

To ensure the implementation of its strategy, the company will systematically carry out nine major strategic initiatives, build eight core capabilities, and solidify five organizational safeguards. Management mechanisms such as business plans, management reports, and performance contracts will be used to monitor and evaluate the full process of strategic plan execution, ensuring solid progress toward strategic goals and value realization.

External research institutions are optimistic about Tasly’s future development. Cinda Securities recently pointed out in a research report that China Resources Sanjiu is a leader in the domestic health consumer goods sector, with industry-leading channel resources and brand capabilities. As a state-owned enterprise under China Resources, it possesses forward-looking strategic planning and market-oriented management ideas. Currently, the integration between the two parties is progressing smoothly, which is expected to bring positive changes to Tasly.